<p>股東們可能注意到，<strong>信越化學株式會社</strong>（TSE:4063）在上週這個時候發佈了第三季度業績。早期反應並不積極，過去一週股價下跌了 8.9%，至 JP¥5,129。信越化學的收入未能達到預期，差距為 2.1%，實際收入為 JP¥6490 億，儘管法定每股收益（EPS）為 JP¥67.51，超出預期，領先分析師預期 5.1%。對於投資者來説，這是一個重要的時刻，因為他們可以在報告中跟蹤公司的表現，查看專家對明年的預測，並觀察業務預期是否有變化。因此，我們收集了最新的財報後預測，以瞭解估計值對明年的展望。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708"/></p>
<p>TSE:4063 收益和收入增長 2026 年 1 月 30 日</p>
<p>考慮到最新的業績，18 位分析師對信越化學的最新共識是 2027 年收入為 JP¥2.71 萬億。如果實現，這將意味着過去 12 個月收入增長 5.5%。法定每股收益預計將增長 13%，達到 JP¥292。然而，在最新業績發佈之前，分析師們曾預計 2027 年收入為 JP¥2.70 萬億，每股收益（EPS）為 JP¥293。共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的因素，因為他們的預期沒有重大變化。</p>
<p>查看我們對信越化學的最新分析</p>
<p>分析師們重申了 JP¥5,582 的目標價，顯示出該業務的執行情況良好，符合預期。然而，這並不是我們可以從這些數據中得出的唯一結論，因為一些投資者在評估分析師目標價時也喜歡考慮估計值的差異。對信越化學的看法存在一些差異，最樂觀的分析師將其估值為 JP¥6,300，而最悲觀的則為每股 JP¥4,600。正如你所看到的，分析師們對該股票的未來並不完全一致，但估計值的範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
<p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長預期進行比較來理解它們。很明顯，市場預期信越化學的收入增長將大幅放緩，預計到 2027 年底的收入年均增長率為 4.4%。相比之下，過去五年的歷史增長率為 9.0%。與行業內其他公司相比，分析師們預計這些公司的收入（總體）年均增長 4.4%。因此，很明顯，儘管信越化學的收入增長預計會放緩，但預計將大致與行業保持一致。</p>
<h2>結論</h2>
<p>最明顯的結論是，最近業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。他們還重申了收入預期，預計公司將以與更廣泛行業相似的速度增長。共識目標價保持在 JP¥5,582，最新的估計不足以對他們的目標價產生影響。</p>
<p>考慮到這一點，我們不會急於對信越化學得出結論。長期的盈利能力遠比明年的利潤重要。我們有來自多位信越化學分析師的估計，直到 2028 年，你可以在我們的平台上免費查看。</p>
<p>那麼風險呢？每家公司都有風險，我們發現了 <strong>信越化學的 2 個警告信號</strong>，你應該知道。</p>

信越化學

SHECY

<p>信越化學報告了其第三季度業績，營收未達到預期，低於預估 2.1%，但每股收益（EPS）超出預期 5.1%。報告發布後，股價下跌 8.9%。分析師預測 2027 年的營收為 2.71 萬億日元，反映出 5.5% 的增長，EPS 預計增長 13%，達到 292 日元。共識目標價維持在 5,582 日元，儘管與歷史增長率相比，營收增長放緩，但仍顯示出穩定的預期。分析師對該股票未來的看法各不相同，但總體估計表明增長與行業平均水平相符</p>

<p>Shareholders might have noticed that <strong>Shin-Etsu Chemical Co., Ltd.</strong> (TSE:4063) filed its third-quarter result this time last week. The early response was not positive, with shares down 8.9% to JP¥5,129 in the past week. Shin-Etsu Chemical missed revenue estimates by 2.1%, coming in atJP¥649b, although statutory earnings per share (EPS) of JP¥67.51 beat expectations, coming in 5.1% ahead of analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>股東們可能注意到，<strong>信越化學株式會社</strong>（TSE:4063）在上週這個時候發佈了第三季度業績。早期反應並不積極，過去一週股價下跌了 8.9%，至 JP¥5,129。信越化學的收入未能達到預期，差距為 2.1%，實際收入為 JP¥6490 億，儘管法定每股收益（EPS）為 JP¥67.51，超出預期，領先分析師預期 5.1%。對於投資者來説，這是一個重要的時刻，因為他們可以在報告中跟蹤公司的表現，查看專家對明年的預測，並觀察業務預期是否有變化。因此，我們收集了最新的財報後預測，以瞭解估計值對明年的展望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708" alt="" original-src="https://images.simplywall.st/asset/chart/874467-earnings-and-revenue-growth-1-dark-2/1769807132708"/></p>
<p>TSE:4063 Earnings and Revenue Growth January 30th 2026</p>
<div class="lb-trans"><p>TSE:4063 收益和收入增長 2026 年 1 月 30 日</p>
</div><p>Taking into account the latest results, the most recent consensus for Shin-Etsu Chemical from 18 analysts is for revenues of JP¥2.71t in 2027. If met, it would imply a satisfactory 5.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to grow 13% to JP¥292. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥2.70t and earnings per share (EPS) of JP¥293 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.</p>
<div class="lb-trans"><p>考慮到最新的業績，18 位分析師對信越化學的最新共識是 2027 年收入為 JP¥2.71 萬億。如果實現，這將意味着過去 12 個月收入增長 5.5%。法定每股收益預計將增長 13%，達到 JP¥292。然而，在最新業績發佈之前，分析師們曾預計 2027 年收入為 JP¥2.70 萬億，每股收益（EPS）為 JP¥293。共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的因素，因為他們的預期沒有重大變化。</p>
</div><p>See our latest analysis for Shin-Etsu Chemical</p>
<div class="lb-trans"><p>查看我們對信越化學的最新分析</p>
</div><p>The analysts reconfirmed their price target of JP¥5,582, showing that the business is executing well and in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Shin-Etsu Chemical, with the most bullish analyst valuing it at JP¥6,300 and the most bearish at JP¥4,600 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>分析師們重申了 JP¥5,582 的目標價，顯示出該業務的執行情況良好，符合預期。然而，這並不是我們可以從這些數據中得出的唯一結論，因為一些投資者在評估分析師目標價時也喜歡考慮估計值的差異。對信越化學的看法存在一些差異，最樂觀的分析師將其估值為 JP¥6,300，而最悲觀的則為每股 JP¥4,600。正如你所看到的，分析師們對該股票的未來並不完全一致，但估計值的範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
</div><p>Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that Shin-Etsu Chemical's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 4.4% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 4.4% annually. So it's pretty clear that, while Shin-Etsu Chemical's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.</p>
<div class="lb-trans"><p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長預期進行比較來理解它們。很明顯，市場預期信越化學的收入增長將大幅放緩，預計到 2027 年底的收入年均增長率為 4.4%。相比之下，過去五年的歷史增長率為 9.0%。與行業內其他公司相比，分析師們預計這些公司的收入（總體）年均增長 4.4%。因此，很明顯，儘管信越化學的收入增長預計會放緩，但預計將大致與行業保持一致。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at JP¥5,582, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最明顯的結論是，最近業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。他們還重申了收入預期，預計公司將以與更廣泛行業相似的速度增長。共識目標價保持在 JP¥5,582，最新的估計不足以對他們的目標價產生影響。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Shin-Etsu Chemical. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Shin-Etsu Chemical analysts - going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>考慮到這一點，我們不會急於對信越化學得出結論。長期的盈利能力遠比明年的利潤重要。我們有來自多位信越化學分析師的估計，直到 2028 年，你可以在我們的平台上免費查看。</p>
</div><p>And what about risks? Every company has them, and we've spotted <strong>2 warning signs for Shin-Etsu Chemical</strong> you should know about.</p>
<div class="lb-trans"><p>那麼風險呢？每家公司都有風險，我們發現了 <strong>信越化學的 2 個警告信號</strong>，你應該知道。</p>
</div>

信越化學公司業績超出分析師預期：看看市場共識對明年的預測